| P2093 | author name string | Roland Haubner | |
| | Christine Rangger | |
| P2860 | cites work | A constitutively active and uninhibitable caspase-3 zymogen efficiently induces apoptosis | Q24647033 |
| | Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD | Q24805375 |
| | Clinical Application of Radiolabeled RGD Peptides for PET Imaging of Integrin αvβ3 | Q26771417 |
| | PET tracers for somatostatin receptor imaging of neuroendocrine tumors: current status and review of the literature | Q26992201 |
| | A remote arene-binding site on prostate specific membrane antigen revealed by antibody-recruiting small molecules | Q27664106 |
| | Structure-Activity Relationship of (18)F-Labeled Phosphoramidate Peptidomimetic Prostate-Specific Membrane Antigen (PSMA)-Targeted Inhibitor Analogues for PET Imaging of Prostate Cancer | Q27705945 |
| | Identification of key residues for interaction of vasoactive intestinal peptide with human VPAC1 and VPAC2 receptors and development of a highly selective VPAC1 receptor agonist. Alanine scanning and molecular modeling of the peptide | Q28143861 |
| | Radiolabeled small-molecule ligands for prostate-specific membrane antigen: in vivo imaging in experimental models of prostate cancer | Q28254156 |
| | Structural biology of copper trafficking | Q28261249 |
| | Protein structure and membrane anchorage of the cellular receptor for urokinase-type plasminogen activator. | Q30354151 |
| | 18F-labeled galacto and PEGylated RGD dimers for PET imaging of αvβ3 integrin expression | Q30497615 |
| | Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data | Q30666654 |
| | The Significance of NK1 Receptor Ligands and Their Application in Targeted Radionuclide Tumour Therapy | Q93080395 |
| | Clinical Application of 18F-AlF-NOTA-Octreotide PET/CT in Combination With 18F-FDG PET/CT for Imaging Neuroendocrine Neoplasms | Q93094169 |
| | Biodistribution and first clinical results of 18F-SiFAlin-TATE PET: a novel 18F-labeled somatostatin analog for imaging of neuroendocrine tumors | Q93163058 |
| | Phase I Study of CTT1057, an 18F-Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate-Specific Membrane Antigen in Prostate Cancer | Q93336393 |
| | Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with 177Lu-PSMA-I&T in Metastatic Castration-resistant Prostate Cancer | Q93352125 |
| | Somatostatin receptor PET ligands - the next generation for clinical practice | Q95360903 |
| | Bifunctional Gallium-68 Chelators: Past, Present, and Future | Q38828564 |
| | 68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies | Q38862313 |
| | [(68)Ga]FSC-(RGD)3 a trimeric RGD peptide for imaging αvβ3 integrin expression based on a novel siderophore derived chelating scaffold-synthesis and evaluation | Q38933775 |
| | Comparison of DOTA and NODAGA as chelators for (64)Cu-labeled immunoconjugates | Q38933889 |
| | VPAC1 Targeted (64)Cu-TP3805 Positron Emission Tomography Imaging of Prostate Cancer: Preliminary Evaluation in Man. | Q38948710 |
| | PET imaging of neovascularization with (68)Ga-3PRGD2 for assessing tumor early response to Endostar antiangiogenic therapy | Q38962718 |
| | An octadentate bifunctional chelating agent for the development of stable zirconium-89 based molecular imaging probes | Q38965023 |
| | Radiofluorination of PSMA-HBED via Al(18)F(2+) Chelation and Biological Evaluations In Vitro | Q39018543 |
| | Evaluation of [(18)F]-CP18 as a PET imaging tracer for apoptosis | Q39150850 |
| | Lutetium 177 PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy. | Q39183360 |
| | Positron emission tomography (PET) imaging of prostate cancer with a gastrin releasing peptide receptor antagonist--from mice to men. | Q39242936 |
| | Urokinase Plasminogen Activator Receptor-PET with 68Ga-NOTA-AE105: First Clinical Experience with a Novel PET Ligand | Q39346734 |
| | 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging | Q39389586 |
| | 177Lu-PSMA Radioligand Therapy for Prostate Cancer | Q39405668 |
| | 3,4,6-Tri-O-acetyl-2-deoxy-2-[18F]fluoroglucopyranosyl Phenylthiosulfonate: A Thiol-Reactive Agent for the Chemoselective18F-Glycosylation of Peptides | Q64030207 |
| | Rational Design, Synthesis and Preliminary Evaluation of Novel Fusarinine C-Based Chelators for Radiolabeling with Zirconium-89 | Q64055515 |
| | Detection Efficacy of F-PSMA-1007 PET/CT in 251 Patients with Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy | Q64080488 |
| | Ga-FAPI PET/CT: Biodistribution and Preliminary Dosimetry Estimate of 2 DOTA-Containing FAP-Targeting Agents in Patients with Various Cancers | Q64080500 |
| | The Search for an Alternative to [Ga]Ga-DOTA-TATE in Neuroendocrine Tumor Theranostics: Current State of F-labeled Somatostatin Analog Development | Q64238307 |
| | Radiolabeling of a monoclonal antibody with N-succinimidyl para-[77Br]bromobenzoate | Q70231451 |
| | Radioiodination by use of the Bolton-Hunter and related reagents | Q70653410 |
| | N-succinimidyl 4-methyl-3-(tri-n-butylstannyl)benzoate: synthesis and potential utility for the radioiodination of monoclonal antibodies | Q70742870 |
| | Characterization of bromine-77-labeled proteins prepared using bromoperoxidase | Q71334136 |
| | One-step synthesis of 18F labeled [18F]-N-succinimidyl 4-(fluoromethyl)benzoate for protein labeling | Q72640088 |
| | Improved synthesis of N-succinimidyl 4-[18F]fluorobenzoate and its application to the labeling of a monoclonal antibody fragment | Q72774298 |
| | Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA0,d-Phe1,Tyr3]octreotide, a promising somatostatin analogue for radionuclide therapy | Q73208012 |
| | A new, convenient method for the preparation of 4-[18F]fluorobenzyl halides | Q73440456 |
| | High yield direct 76Br-bromination of monoclonal antibodies using chloramine-T | Q73524505 |
| | Value of peptide receptor scintigraphy using (123)I-vasoactive intestinal peptide and (111)In-DTPA-D-Phe1-octreotide in 194 carcinoid patients: Vienna University Experience, 1993 to 1998 | Q73544190 |
| | Synthesis, conjugation, and radiolabeling of a novel bifunctional chelating agent for (225)Ac radioimmunotherapy applications | Q74013187 |
| | Radiolabeled alpha(v)beta3 integrin antagonists: a new class of tracers for tumor targeting | Q78143346 |
| | Reagents for astatination of biomolecules. 2. Conjugation of anionic boron cage pendant groups to a protein provides a method for direct labeling that is stable to in vivo deastatination | Q80510964 |
| | [18F]azadibenzocyclooctyne ([18F]ADIBO): a biocompatible radioactive labeling synthon for peptides using catalyst free [3+2] cycloaddition | Q82176429 |
| | TRAP, a powerful and versatile framework for gallium-68 radiopharmaceuticals | Q82836384 |
| | Elucidation of the structure-activity relationships of apelin: influence of unnatural amino acids on binding, signaling, and plasma stability | Q82967241 |
| | Unexpected sensitivity of sst2 antagonists to N-terminal radiometal modifications | Q84696636 |
| | Development of Quinoline-Based Theranostic Ligands for the Targeting of Fibroblast Activation Protein | Q88295170 |
| | [68Ga]Ga-Pentixafor PET/MRI for CXCR4 Imaging of Chronic Lymphocytic Leukemia: Preliminary Results | Q88331008 |
| | Feasibility of CXCR4-Directed Radioligand Therapy in Advanced Diffuse Large B-Cell Lymphoma | Q88732366 |
| | Application of Cu-64 NODAGA-PSMA PET in Prostate Cancer | Q88734007 |
| | Clinical Applications of Radiolabeled Peptides for PET | Q88820027 |
| | What about αvβ3 integrins in molecular imaging in oncology? | Q88882824 |
| | Targeting of the Cholecystokinin-2 Receptor with the Minigastrin Analog 177Lu-DOTA-PP-F11N: Does the Use of Protease Inhibitors Further Improve In Vivo Distribution? | Q90006784 |
| | PET-Based Human Dosimetry of 68Ga-NODAGA-Exendin-4, a Tracer for β-Cell Imaging | Q90100192 |
| | Development of Novel PSMA Ligands for Imaging and Therapy with Copper Isotopes | Q90196809 |
| | Comparison of glucagon-like peptide-1 receptor (GLP-1R) PET/CT, SPECT/CT and 3T MRI for the localisation of occult insulinomas: evaluation of diagnostic accuracy in a prospective crossover imaging study | Q90582323 |
| | Availability of both [177Lu]Lu-DOTA-TATE and [90Y]Y-DOTATATE as PRRT agents for neuroendocrine tumors: can we evolve a rational sequential duo-PRRT protocol for large volume resistant tumors? | Q90813537 |
| | Bench to Bedside: Albumin Binders for Improved Cancer Radioligand Therapies | Q90925164 |
| | Single Low-Dose Injection of Evans Blue Modified PSMA-617 Radioligand Therapy Eliminates Prostate-Specific Membrane Antigen Positive Tumors | Q90935531 |
| | AAZTA5/AAZTA5-TOC: synthesis and radiochemical evaluation with 68Ga, 44Sc and 177Lu | Q90976884 |
| | Comparison of 68Ga-labeled RGD mono- and multimers based on a clickable siderophore-based scaffold | Q91072082 |
| | Broadening horizons with 225Ac-DOTATATE targeted alpha therapy for gastroenteropancreatic neuroendocrine tumour patients stable or refractory to 177Lu-DOTATATE PRRT: first clinical experience on the efficacy and safety | Q91211980 |
| | Intraperitoneal α-Emitting Radioimmunotherapy with 211At in Relapsed Ovarian Cancer: Long-Term Follow-up with Individual Absorbed Dose Estimations | Q91228900 |
| | Pretreatment PET/CT imaging of angiogenesis based on 18F-RGD tracer uptake may predict antiangiogenic response | Q91308795 |
| | 225Ac-PSMA-617/177Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer: pilot experience | Q91405943 |
| | Radiation Dosimetry and Biodistribution of 18F-PSMA-11 for PET Imaging of Prostate Cancer | Q91556506 |
| | An 18F-Labeled PSMA Ligand for PET/CT of Prostate Cancer: First-in-Humans Observational Study and Clinical Experience with 18F-JK-PSMA-7 During the First Year of Application | Q92034000 |
| | [68Ga]Ga-P16-093 as a PSMA-Targeted PET Radiopharmaceutical for Detection of Cancer: Initial Evaluation and Comparison with [68Ga]Ga-PSMA-11 in Prostate Cancer Patients Presenting with Biochemical Recurrence | Q92718603 |
| | A Systematic Review on the Role of Imaging in Early Recurrent Prostate Cancer | Q92726320 |
| | Phase I Trial of Well-Differentiated Neuroendocrine Tumors (NETs) with Radiolabeled Somatostatin Antagonist 177Lu-Satoreotide Tetraxetan | Q92794489 |
| | 68Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer | Q92898068 |
| | PSMA-Targeted Radiopharmaceuticals for Imaging and Therapy | Q92943151 |
| | CXCR4-Directed Imaging in Solid Tumors | Q93048437 |
| | 2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer | Q39449818 |
| | Strain-promoted copper-free "click" chemistry for 18F radiolabeling of bombesin | Q39466193 |
| | Novel (64)Cu- and (68)Ga-labeled RGD conjugates show improved PET imaging of α(ν)β(3) integrin expression and facile radiosynthesis | Q39505469 |
| | [68Ga]NODAGA-RGD for imaging αvβ3 integrin expression. | Q39559499 |
| | One step radiosynthesis of 6-[(18)F]fluoronicotinic acid 2,3,5,6-tetrafluorophenyl ester ([(18)F]F-Py-TFP): a new prosthetic group for efficient labeling of biomolecules with fluorine-18. | Q39750040 |
| | Clinical Translation of a Click-Labeled 18F-Octreotate Radioligand for Imaging Neuroendocrine Tumors. | Q39771221 |
| | Noninvasive imaging of alphaVbeta3 function as a predictor of the antimigratory and antiproliferative effects of dasatinib | Q39868638 |
| | Disparity between in vivo EGFR expression and 89Zr-labeled cetuximab uptake assessed with PET. | Q39903960 |
| | A stable neurotensin-based radiopharmaceutical for targeted imaging and therapy of neurotensin receptor-positive tumours | Q39952444 |
| | Synthesis and evaluation of technetium-99m- and rhenium-labeled inhibitors of the prostate-specific membrane antigen (PSMA). | Q39959750 |
| | Radiosynthesis and biodistribution of cyclic RGD peptides conjugated with novel [18F]fluorinated aldehyde-containing prosthetic groups | Q40002427 |
| | Pilot Comparison of ⁶⁸Ga-RM2 PET and ⁶⁸Ga-PSMA-11 PET in Patients with Biochemically Recurrent Prostate Cancer | Q40219589 |
| | Pilot prospective evaluation of (18)F-FPPRGD2 PET/CT in patients with cervical and ovarian cancer | Q40270232 |
| | First (18)F-labeled tracer suitable for routine clinical imaging of sst receptor-expressing tumors using positron emission tomography | Q40550081 |
| | Use of the incretin hormone glucagon-like peptide-1 (GLP-1) for the detection of insulinomas: initial experimental results | Q40735721 |
| | Localization of Hidden Insulinomas with ⁶⁸Ga-DOTA-Exendin-4 PET/CT: A Pilot Study | Q40913283 |
| | VPAC1 receptors for imaging breast cancer: a feasibility study | Q40991225 |
| | [177Lu]pentixather: Comprehensive Preclinical Characterization of a First CXCR4-directed Endoradiotherapeutic Agent. | Q41114242 |
| | Exploring the Role of RGD-Recognizing Integrins in Cancer | Q41670915 |
| | 89Zr-Immuno-Positron Emission Tomography in Oncology: State-of-the-Art 89Zr Radiochemistry. | Q41690954 |
| | 213Bi-PSMA-617 targeted alpha-radionuclide therapy in metastatic castration-resistant prostate cancer. | Q41856358 |
| | N-[N-[(S)-1,3-Dicarboxypropyl]carbamoyl]-4-[18F]fluorobenzyl-L-cysteine, [18F]DCFBC: a new imaging probe for prostate cancer | Q41913170 |
| | 89Zr-bevacizumab PET of early antiangiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922. | Q43097928 |
| | Radiohalogenated prostate-specific membrane antigen (PSMA)-based ureas as imaging agents for prostate cancer | Q43193122 |
| | Direct one-step 18F-labeling of peptides via nucleophilic aromatic substitution | Q43239777 |
| | Direct labelling of peptides with 2-[18F]fluoro-2-deoxy-d-glucose ([18F]FDG). | Q43295652 |
| | In vitro stability and in vivo clearance of fibrinogen or serum albumin labeled with 77Br, 131I, or 125I by direct or indirect synthetic methods. | Q43500223 |
| | Noninvasive imaging of alpha(v)beta3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography | Q43561095 |
| | PET imaging of somatostatin receptors using [68GA]DOTA-D-Phe1-Tyr3-octreotide: first results in patients with meningiomas | Q43662898 |
| | High-level production of alpha-particle-emitting (211)At and preparation of (211)At-labeled antibodies for clinical use. | Q43755984 |
| | Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression. | Q44275821 |
| | Cholecystokinin-B (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies | Q44377511 |
| | Optimising conditions for radiolabelling of DOTA-peptides with 90Y, 111In and 177Lu at high specific activities | Q44391489 |
| | Radiolabelling of isopeptide N epsilon-(gamma-glutamyl)-L-lysine by conjugation with N-succinimidyl-4-[18F]fluorobenzoate | Q44523672 |
| | DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals | Q44561169 |
| | Synthesis of a New Heterobifunctional Linker, N-[4-(Aminooxy)butyl]maleimide, for Facile Access to a Thiol-Reactive 18F-Labeling Agent | Q44660414 |
| | [18F]Galacto-RGD: synthesis, radiolabeling, metabolic stability, and radiation dose estimates | Q44735126 |
| | Synthesis of urea-based inhibitors as active site probes of glutamate carboxypeptidase II: efficacy as analgesic agents | Q44803462 |
| | Two-step methodology for high-yield routine radiohalogenation of peptides: (18)F-labeled RGD and octreotide analogs | Q44891219 |
| | Development and characterization of clinical-grade 89Zr-trastuzumab for HER2/neu immunoPET imaging | Q44944204 |
| | 18F-fluorothiols: a new approach to label peptides chemoselectively as potential tracers for positron emission tomography | Q45152183 |
| | (18)F-Fluoroglucosylation of peptides, exemplified on cyclo(RGDfK). | Q46059201 |
| | A series of 2-O-trifluoromethylsulfonyl-D-mannopyranosides as precursors for concomitant 18F-labeling and glycosylation by click chemistry | Q46080179 |
| | microPET imaging of glioma integrin {alpha}v{beta}3 expression using (64)Cu-labeled tetrameric RGD peptide | Q46115376 |
| | para-Functionalized aryl-di-tert-butylfluorosilanes as potential labeling synthons for (18)F radiopharmaceuticals | Q46155047 |
| | Biodistribution and radiation dosimetry of the integrin marker 18F-RGD-K5 determined from whole-body PET/CT in monkeys and humans | Q46173308 |
| | In vivo imaging of prostate cancer using [68Ga]-labeled bombesin analog BAY86-7548. | Q46234834 |
| | The biodistribution and radiation dosimetry of the Arg-Gly-Asp peptide 18F-AH111585 in healthy volunteers | Q46365501 |
| | Direct procedure for the production of 211At-labeled antibodies with an epsilon-lysyl-3-(trimethylstannyl)benzamide immunoconjugate | Q46429197 |
| | Development of ⁶⁸Ga-labelled DTPA galactosyl human serum albumin for liver function imaging | Q46566508 |
| | Synthesis and application of [18F]FDG-maleimidehexyloxime ([18F]FDG-MHO): a [18F]FDG-based prosthetic group for the chemoselective 18F-labeling of peptides and proteins | Q46594513 |
| | Biodistribution and pharmacokinetics of the alphavbeta3-selective tracer 18F-galacto-RGD in cancer patients | Q46639250 |
| | Preparation of a promising angiogenesis PET imaging agent: 68Ga-labeled c(RGDyK)-isothiocyanatobenzyl-1,4,7-triazacyclononane-1,4,7-triacetic acid and feasibility studies in mice | Q46643953 |
| | Tailored Gallium(III) chelator NOPO: synthesis, characterization, bioconjugation, and application in preclinical Ga-68-PET imaging. | Q30718053 |
| | "Click labeling" with 2-[18f]fluoroethylazide for positron emission tomography. | Q30831041 |
| | Radiolabeled tracers for imaging of tumor angiogenesis and evaluation of anti-angiogenic therapies | Q31059628 |
| | [(68)Ga]NODAGA-RGD - Metabolic stability, biodistribution, and dosimetry data from patients with hepatocellular carcinoma and liver cirrhosis | Q31095114 |
| | 64Cu-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors. | Q32053886 |
| | Imaging of integrin alpha(v)beta(3) expression in patients with malignant glioma by [18F] Galacto-RGD positron emission tomography | Q33574585 |
| | CXCR4-directed endoradiotherapy induces high response rates in extramedullary relapsed Multiple Myeloma | Q33703097 |
| | Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6 | Q33705446 |
| | [(18)F]-NHC-BF3 adducts as water stable radio-prosthetic groups for PET imaging | Q33759239 |
| | Alternative chelator for ⁸⁹Zr radiopharmaceuticals: radiolabeling and evaluation of 3,4,3-(LI-1,2-HOPO). | Q33761754 |
| | Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients | Q33841484 |
| | In vivo transchelation of copper-64 from TETA-octreotide to superoxide dismutase in rat liver. | Q33909857 |
| | 89Zr immuno-PET: comprehensive procedures for the production of 89Zr-labeled monoclonal antibodies | Q34220197 |
| | Recent progress in fluorine-18 labelled peptide radiopharmaceuticals | Q34336436 |
| | Peptidomimetics, a synthetic tool of drug discovery | Q34656152 |
| | Somatostatin analogs and radiopeptides in cancer therapy | Q34972896 |
| | Pilot pharmacokinetic and dosimetric studies of (18)F-FPPRGD2: a PET radiopharmaceutical agent for imaging α(v)β(3) integrin levels | Q35062113 |
| | Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors | Q35103872 |
| | New Methods for Labeling RGD Peptides with Bromine-76. | Q35224462 |
| | Disclosing the CXCR4 expression in lymphoproliferative diseases by targeted molecular imaging | Q35227508 |
| | PET imaging of early response to the tyrosine kinase inhibitor ZD4190. | Q35249646 |
| | In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma | Q35483867 |
| | Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer. | Q35604902 |
| | Comparison study of [18F]FAl-NOTA-PRGD2, [18F]FPPRGD2, and [68Ga]Ga-NOTA-PRGD2 for PET imaging of U87MG tumors in mice | Q35629161 |
| | Prospective Study of (68)Ga-NOTA-NFB: Radiation Dosimetry in Healthy Volunteers and First Application in Glioma Patients | Q35633357 |
| | In vitro and in vivo evaluation of a 64Cu-labeled NOTA-Bn-SCN-Aoc-bombesin analogue in gastrin-releasing peptide receptor expressing prostate cancer | Q35925945 |
| | First-in-human uPAR PET: Imaging of Cancer Aggressiveness | Q36191589 |
| | (18)F-Alfatide II PET/CT in healthy human volunteers and patients with brain metastases | Q36225629 |
| | Synthesis and preclinical evaluation of bifunctional ligands for improved chelation chemistry of 90Y and 177Lu for targeted radioimmunotherapy | Q36247600 |
| | Production of [(211)At]-astatinated radiopharmaceuticals and applications in targeted α-particle therapy | Q36534262 |
| | Fluorine-18 labeling of peptides and proteins. | Q36685391 |
| | In Vitro and In Vivo Comparison of Selected Ga-68 and Zr-89 Labelled Siderophores. | Q36909826 |
| | First experience of 18F-alfatide in lung cancer patients using a new lyophilized kit for rapid radiofluorination | Q36931413 |
| | Gastrin-releasing Peptide Receptor Imaging in Breast Cancer Using the Receptor Antagonist (68)Ga-RM2 And PET. | Q37112967 |
| | Intraperitoneal alpha-particle radioimmunotherapy of ovarian cancer patients: pharmacokinetics and dosimetry of (211)At-MX35 F(ab')2--a phase I study. | Q50605886 |
| | Synthesis of [18F]RGD-K5 by catalyzed [3 + 2] cycloaddition for imaging integrin αvβ3 expression in vivo. | Q50961964 |
| | Prolonged survival in secondary glioblastoma following local injection of targeted alpha therapy with 213Bi-substance P analogue. | Q52715248 |
| | 225Ac-PSMA-617 for PSMA-Targeted α-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer. | Q52981848 |
| | Medullary thyroid carcinoma - PET/CT imaging with 68Ga-labelled gastrin and somatostatin analogues. | Q52984876 |
| | First Experience with Chemokine Receptor CXCR4-Targeted PET Imaging of Patients with Solid Cancers. | Q52985671 |
| | Biodistribution and radiation dosimetry of 18F-CP-18, a potential apoptosis imaging agent, as determined from PET/CT scans in healthy volunteers. | Q53091381 |
| | PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. | Q53131398 |
| | Be spoilt for choice with radiolabelled RGD peptides: preclinical evaluation of ⁶⁸Ga-TRAP(RGD)₃. | Q53140894 |
| | 68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors. | Q53192267 |
| | Synthesis and in vitro evaluation of [18F]fluoroethyl triazole labelled [Tyr3]octreotate analogues using click chemistry. | Q53234108 |
| | Kit-like 18F-labeling of proteins: synthesis of 4-(di-tert-butyl[18F]fluorosilyl)benzenethiol (Si[18F]FA-SH) labeled rat serum albumin for blood pool imaging with PET. | Q53375642 |
| | Positron emission tomography using [18F]Galacto-RGD identifies the level of integrin alpha(v)beta3 expression in man. | Q53530857 |
| | Gluc-Lys([18F]FP)-TOCA PET in patients with SSTR-positive tumors: biodistribution and diagnostic evaluation compared with [111In]DTPA-octreotide. | Q53543895 |
| | Arg-Gly-Asp constrained within cyclic pentapeptides. Strong and selective inhibitors of cell adhesion to vitronectin and laminin fragment P1. | Q53686513 |
| | Small Prosthetic Groups in 18F-Radiochemistry: Useful Auxiliaries for the Design of 18F-PET Tracers. | Q54246542 |
| | Site-specific stabilization of minigastrin analogs against enzymatic degradation for enhanced cholecystokinin-2 receptor targeting. | Q55098217 |
| | Pharmacokinetic studies of ⁶⁸Ga-labeled Bombesin (⁶⁸Ga-BZH₃) and F-18 FDG PET in patients with recurrent gliomas and comparison to grading: preliminary results. | Q55463516 |
| | First-in-human study of Lu-EB-PSMA-617 in patients with metastatic castration-resistant prostate cancer | Q56523728 |
| | Automated radiosynthesis of N-succinimidyl 3-(di-tert-butyl[(18)F]fluorosilyl)benzoate ([(18)F]SiFB) for peptides and proteins radiolabeling for positron emission tomography | Q57041065 |
| | Targeted α-therapy of prostate cancer using radiolabeled PSMA inhibitors: a game changer in nuclear medicine | Q57107703 |
| | Head-to-Head Comparison of 64 Cu-DOTATATE and 68 Ga-DOTATOC PET/CT: A Prospective Study of 59 Patients with Neuroendocrine Tumors | Q57680025 |
| | Comparison of 68Ga-DOTATATE and 68Ga-DOTANOC PET/CT imaging in the same patient group with neuroendocrine tumours | Q57757597 |
| | Discovery of F-JK-PSMA-7, a novel PET-probe for the detection of small PSMA positive lesions | Q58617086 |
| | CXCR4-directed theranostics in oncology and inflammation | Q58783862 |
| | An Overview of Targeted Alpha Therapy with Actinium and Bismuth | Q59796859 |
| | Development of Ac Radiopharmaceuticals: TRIUMF Perspectives and Experiences | Q60048015 |
| | Structure and stability of hexadentate complexes of ligands based on AAZTA for efficient PET labelling with gallium-68 | Q60171678 |
| | Chemoselective hydrazone formation between HYNIC-functionalized peptides and 18F-fluorinated aldehydes | Q60607032 |
| | [18F]galacto-RGD positron emission tomography for imaging of alphavbeta3 expression on the neovasculature in patients with squamous cell carcinoma of the head and neck | Q46897615 |
| | Dual Targeting of Acute Leukemia and Supporting Niche by CXCR4-Directed Theranostics. | Q47114899 |
| | Current status of theranostics in prostate cancer. | Q47241139 |
| | Comparison of 68Ga-OPS202 (68Ga-NODAGA-JR11) and 68Ga-DOTATOC (68Ga-Edotreotide) PET/CT in Patients with Gastroenteropancreatic Neuroendocrine Tumors: Evaluation of Sensitivity in a Prospective Phase II Imaging Study | Q47388629 |
| | Clinical PET of neuroendocrine tumors using 64Cu-DOTATATE: first-in-humans study | Q47399002 |
| | Intra-individual comparison of 18F-PSMA-1007 and 18F-DCFPyL PET/CT in the prospective evaluation of patients with newly diagnosed prostate carcinoma: A pilot study | Q47572465 |
| | Specific inactivation of sensitized lymphocytes in vitro using antigens labelled with astatine-211 | Q47988801 |
| | Radiotoxicity of systemically administered 211At-labeled human/mouse chimeric monoclonal antibody: a long-term survival study with histologic analysis | Q48112253 |
| | In Vivo Evaluation of ¹⁸F-SiFAlin-Modified TATE: A Potential Challenge for ⁶⁸Ga-DOTATATE, the Clinical Gold Standard for Somatostatin Receptor Imaging with PET. | Q48175950 |
| | GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting | Q48180523 |
| | Comparison of PSMA-HBED and PSMA-I&T as diagnostic agents in prostate carcinoma. | Q48188322 |
| | Imaging Characteristics and First Experience of [68Ga]THP-PSMA, a Novel Probe for Rapid Kit-Based Ga-68 Labeling and PET Imaging: Comparative Analysis with [68Ga]PSMA I&T. | Q48221776 |
| | 177Lu-PSMA-617 radioligand therapy in mCRPC: ready for phase III trial? | Q48257941 |
| | An Eighteen-Membered Macrocyclic Ligand for Actinium-225 Targeted Alpha Therapy | Q48265569 |
| | Design, synthesis, and initial evaluation of high-affinity technetium bombesin analogues | Q48487776 |
| | Automated radiosynthesis of Al[18F]PSMA-11 for large scale routine use. | Q49031791 |
| | 18F-AlF Labeled Peptide and Protein Conjugates as Positron Emission Tomography (PET) Imaging Pharmaceuticals. | Q49797952 |
| | Targeted positron emission tomography imaging of CXCR4 expression in patients with acute myeloid leukemia | Q37140477 |
| | A practical guide to the construction of radiometallated bioconjugates for positron emission tomography. | Q37172093 |
| | H(4)octapa-trastuzumab: versatile acyclic chelate system for 111In and 177Lu imaging and therapy | Q37209655 |
| | (64)Cu-labeled CB-TE2A and diamsar-conjugated RGD peptide analogs for targeting angiogenesis: comparison of their biological activity | Q37218456 |
| | [(64) Cu]-labelled trastuzumab: optimisation of labelling by DOTA and NODAGA conjugation and initial evaluation in mice | Q37268891 |
| | Optimization of Early Response Monitoring and Prediction of Cancer Antiangiogenesis Therapy via Noninvasive PET Molecular Imaging Strategies of Multifactorial Bioparameters | Q37291272 |
| | Integrin α(v)β₃-targeted radiotracer (99m)Tc-3P-RGD₂ useful for noninvasive monitoring of breast tumor response to antiangiogenic linifanib therapy but not anti-integrin α(v)β₃ RGD₂ therapy | Q37344824 |
| | Radiolabelled RGD peptides and peptidomimetics for tumour targeting | Q37410058 |
| | Copper-64 radiopharmaceuticals for PET imaging of cancer: advances in preclinical and clinical research | Q37478003 |
| | [68Ga]Pentixafor-PET/CT for imaging of chemokine receptor CXCR4 expression in multiple myeloma - Comparison to [18F]FDG and laboratory values | Q37541868 |
| | Comparison of the octadentate bifunctional chelator DFO*-pPhe-NCS and the clinically used hexadentate bifunctional chelator DFO-pPhe-NCS for 89Zr-immuno-PET | Q37560052 |
| | 68Ga-NOTA-PRGD2 PET/CT for Integrin Imaging in Patients with Lung Cancer | Q37575733 |
| | Glucagon-Like Peptide-1 Receptor PET/CT with 68Ga-NOTA-Exendin-4 for Detecting Localized Insulinoma: A Prospective Cohort Study | Q37581371 |
| | Peptide-based imaging agents for cancer detection | Q37585965 |
| | Longitudinal PET imaging of muscular inflammation using 18F-DPA-714 and 18F-Alfatide II and differentiation with tumors | Q37663675 |
| | Radiolabeled bombesin derivatives for preclinical oncological imaging. | Q37674035 |
| | Zirconium tetraazamacrocycle complexes display extraordinary stability and provide a new strategy for zirconium-89-based radiopharmaceutical development. | Q37718007 |
| | (2S)-2-(3-(1-Carboxy-5-(4-211At-Astatobenzamido)Pentyl)Ureido)-Pentanedioic Acid for PSMA-Targeted α-Particle Radiopharmaceutical Therapy | Q37722429 |
| | Homeostatic chemokine receptors and organ-specific metastasis | Q37922092 |
| | Radiobromine-labelled tracers for positron emission tomography: possibilities and pitfalls. | Q37970739 |
| | PET tracers based on Zirconium-89. | Q37970745 |
| | Actinium-225 in targeted alpha-particle therapeutic applications. | Q37971807 |
| | A review on CXCR4/CXCL12 axis in oncology: no place to hide. | Q38017493 |
| | Click-to-Chelate: development of technetium and rhenium-tricarbonyl labeled radiopharmaceuticals | Q38088564 |
| | Matching chelators to radiometals for radiopharmaceuticals | Q38156660 |
| | Chelators for copper radionuclides in positron emission tomography radiopharmaceuticals | Q38172069 |
| | PET radiopharmaceuticals for imaging integrin expression: tracers in clinical studies and recent developments. | Q38228356 |
| | GLP-1 and exendin-4 for imaging endocrine pancreas. A review. Labelled glucagon-like peptide-1 analogues: past, present and future | Q38365438 |
| | Molecular Pathways: Targeting the CXCR4-CXCL12 Axis--Untapped Potential in the Tumor Microenvironment | Q38551844 |
| | Preclinical Evaluation of 18F-PSMA-1007, a New Prostate-Specific Membrane Antigen Ligand for Prostate Cancer Imaging. | Q38735685 |
| | Theranostic Perspectives in Prostate Cancer with the Gastrin-Releasing Peptide Receptor Antagonist NeoBOMB1: Preclinical and First Clinical Results | Q38753711 |
| | Toward the Optimization of Bombesin-Based Radiotracers for Tumor Targeting. | Q38780032 |
| | PSA-Stratified Performance of 18F- and 68Ga-PSMA PET in Patients with Biochemical Recurrence of Prostate Cancer. | Q38788408 |
| | Preclinical and first clinical experience with the gastrin-releasing peptide receptor-antagonist [⁶⁸Ga]SB3 and PET/CT. | Q38814811 |
| | Comparison of the Therapeutic Response to Treatment with a 177Lu-Labeled Somatostatin Receptor Agonist and Antagonist in Preclinical Models. | Q38823932 |
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 2 | |
| P921 | main subject | positron emission tomography | Q208376 |
| P577 | publication date | 2020-01-30 | |
| P1433 | published in | Pharmaceuticals | Q15750667 |
| P1476 | title | Radiolabelled Peptides for Positron Emission Tomography and Endoradiotherapy in Oncology | |
| P478 | volume | 13 | |